Related Experiment Video
Updated: Feb 4, 2026

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
Published on: August 22, 2012
Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for
Lawrence C Ku1,2, Christoph P Hornik1,2, Ryan J Beechinor3
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Insights
This study developed a pharmacokinetic model for intravenous diazepam in pediatric patients with status epilepticus (SE). The findings suggest the study dose more effectively and rapidly achieves therapeutic drug concentrations compared to standard dosing.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Status epilepticus (SE) in children requires effective treatment, with diazepam being a labeled option.
- Limited pharmacokinetic (PK) data exist for intravenous (i.v.) diazepam in pediatric populations.
- Understanding diazepam disposition is crucial for optimizing SE treatment in children.
Purpose of the Study:
- To develop a population pharmacokinetic (PK) model for i.v. diazepam in pediatric patients experiencing SE.
- To assess the relationship between diazepam PK parameters and clinical safety and efficacy.
- To simulate drug exposures based on different dosing regimens.
Main Methods:
- A population PK model was developed using data from a prospective pediatric clinical trial.
- Data included 162 diazepam concentrations from 87 patients (3 months to <18 years).
- A two-compartment model, scaled by body size, characterized diazepam PKs.
Main Results:
- Diazepam disposition in pediatric SE was well-described by a body-size-scaled two-compartment model.
- No significant correlations were found between PK parameters and safety or efficacy outcomes.
- Simulations indicated the study dose (0.2 mg/kg i.v.) achieved target therapeutic ranges (200-600 ng/mL) more frequently and rapidly than label dosing.
Conclusions:
- The developed population PK model accurately characterizes diazepam disposition in pediatric SE.
- The study dose of diazepam demonstrates improved therapeutic concentration achievement compared to label dosing.
- Further research may refine pediatric diazepam dosing strategies for status epilepticus.
Abstract:
Diazepam is labeled for status epilepticus (SE) in children, but there are limited data characterizing its disposition in pediatric patients. We developed a population pharmacokinetic (PK) model of i.v. diazepam in children with SE. We evaluated relationships between PK parameters and both safety and efficacy, and simulated exposures using dosing regimens from the product label and clinical practice. The model was developed using prospective data from a pediatric clinical trial comparing diazepam to lorazepam for treatment of SE. Altogether, 87 patients aged ≥ 3 months to < 18 years contributed 162 diazepam concentrations. Diazepam PKs were well characterized by a two-compartment model scaled by body size. No significant or clinically important relationships were observed between diazepam PKs and safety or efficacy. Simulations demonstrated that, compared with label dosing, the study dose (0.2 mg/kg i.v., maximum 8 mg) resulted in greater frequency in rapidly achieving the target therapeutic range of 200-600 ng/mL.
More Related Videos
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
15:00Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Dose-Response Relationship: Overview
Relationship Formation
Dose-Response Relationship: Potency and Efficacy
Dose-Response Relationship: Selectivity and Specificity
Ending Relationships